Volex (AIM: VLX) upgrades FY2026 revenue to at least $1.22bn as AI data centre demand doubles and board eyes Main Market move
Can inhaled nintedanib improve tolerability and adherence in IPF treatment, according to Avalyn Pharma Inc.?
Read More 3 minute read Pharma Industry News Cassava Sciences stock craters after Alzheimer’s drug trial flops in critical phase Cassava Sciences, Inc., a clinical-stage biotechnology company, revealed a significant setback in its pursuit of an effective treatment… byPallavi MadhirajuNovember 25, 2024